EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview

Haneen M Abdalhadi iD, Walter W Chatham, Fatima K Alduraibi iD

International Journal of Molecular Sciences · 29.09.2024 · 25 (19) · 10511

DOI: 10.3390/ijms251910511 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.09.2024. Verfasst von Haneen M Abdalhadi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the production of autoreactive B and T cells and cytokines, leading to chronic inflammation affecting multiple organs. SLE is associated with significant complications that substantially increase morbidity and mortality. Given its complex pathogenesis, conventional treatments for SLE often have significant side effects and limited efficacy, necessitating the exploration of novel therapeutic strategies. One promising approach is the use of chimeric antigen receptor (CAR)-T-cell therapy, which has shown remarkable success in treating refractory hematological malignancies. This review provides a comprehensive analysis of the current use of CAR-T-cell therapy in SLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansAnimals

Stichwörter der Autor:innen

B cellsCAR-T-cell therapysystemic lupus erythematosus

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Nevada, Las Vegas, NV 89102, USA.
  • Department of Medicine, Division of Clinical Immunology and Rheumatology, Harvard Teaching Hospital, Boston, MA 02215, USA.
  • Department of Medicine, Division of Clinical Immunology and Rheumatology, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.

ORCID-Profile: Haneen M Abdalhadi, Fatima K Alduraibi

Zitieren

APA

Abdalhadi, H. M., Chatham, W. W., & Alduraibi, F. K. (2024). CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview. International Journal of Molecular Sciences, 25(19), 10511. https://doi.org/10.3390/ijms251910511

Vancouver

Abdalhadi HM, Chatham WW, Alduraibi FK. CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview. International Journal of Molecular Sciences. 2024;25(19):10511. doi:10.3390/ijms251910511

BibTeX
@article{Abdalhadi2024,
  author = {Abdalhadi, Haneen M and Chatham, Walter W and Alduraibi, Fatima K},
  title = {CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {19},
  pages = {10511},
  doi = {10.3390/ijms251910511}
}
Kostenlos starten →